<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35453591</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">2227-9059</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>10</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>03</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biomedicines</Title>
          <ISOAbbreviation>Biomedicines</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Treatment of Painful Palmoplantar Keratoderma Related to Pachyonychia Congenita Using EGFR Inhibitors.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">841</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines10040841</ELocationID>
        <Abstract>
          <AbstractText>Pachyonychia congenita (PC) is a genodermatosis associated with severe painful palmoplantar keratoderma (PPK) and thickened dystrophic nails caused by autosomal dominant-negative mutations in five genes encoding keratins 6A-B-C, 16, and 17. The mechanical, surgical, or medical options for painful PC are inefficient. Given ErbB/Her family members' role in epidermal homeostasis, this study sought to investigate the possibility of treating PC patients with PPK by blocking signaling either with EGFR (Her1) inhibitor erlotinib or lapatinib, a dual EGFR(Her1)/Her2. After 1 month of therapy with oral erlotinib treatment at 75 mg/day, the pain disappeared for patient #1, with partially reduced hyperkeratosis, while increasing the dose to 100 mg/day resulted in painful skin fissures. Therapy replacement with erlotinib cream at 0.2% was inconclusive, and substitution with oral lapatinib at alternating doses of 500 and 750 mg/day achieved a good compromise between pain reduction, symptom improvements, and side effects. Patient #2's treatment with erlotinib cream failed to display significant improvements. Oral erlotinib started at 75 mg/day then reduced to 25 mg/day because of the formation of an acneiform rash. Treatment considerably improved the patient's condition, with an almost complete disappearance of pain. Oral Her1 or 1/2 inhibitors reduced pain, improved two PC patients' quality of life, and offered promising therapeutic perspectives.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Greco</LastName>
            <ForeName>Céline</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pain and Palliative Care, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris (AP-HP), 75015 Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>IMAGINE Institute, Inserm U1163, Université de Paris, 75015 Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ponsen</LastName>
            <ForeName>Anne-Charlotte</ForeName>
            <Initials>AC</Initials>
            <AffiliationInfo>
              <Affiliation>IMAGINE Institute, Inserm U1163, Université de Paris, 75015 Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leclerc-Mercier</LastName>
            <ForeName>Stéphanie</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0003-2468-3910</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Reference Center for Genodermatoses (MAGEC), Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris (AP-HP), 75015 Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schlatter</LastName>
            <ForeName>Joël</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-4443-8843</Identifier>
            <AffiliationInfo>
              <Affiliation>Service Pharmacie, Hôpital Paul Doumer, Assistance Publique Hôpitaux de Paris (AP-HP), 60332 Liancourt, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cisternino</LastName>
            <ForeName>Salvatore</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-8500-3574</Identifier>
            <AffiliationInfo>
              <Affiliation>Service Pharmacie, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris (AP-HP), 75015 Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculté de Pharmacie, Optimisation, UMRS-1144, Université de Paris, INSERM, 75006 Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boucheix</LastName>
            <ForeName>Claude</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0003-4184-7008</Identifier>
            <AffiliationInfo>
              <Affiliation>Inserm UMRS-MD-1197, Université Paris-Saclay, 94800 Villejuif, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bodemer</LastName>
            <ForeName>Christine</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>IMAGINE Institute, Inserm U1163, Université de Paris, 75015 Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Reference Center for Genodermatoses (MAGEC), Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris (AP-HP), 75015 Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Biomedicines</MedlineTA>
        <NlmUniqueID>101691304</NlmUniqueID>
        <ISSNLinking>2227-9059</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">EGFR</Keyword>
        <Keyword MajorTopicYN="N">pachyonychia congenita</Keyword>
        <Keyword MajorTopicYN="N">pain</Keyword>
        <Keyword MajorTopicYN="N">palmoplantar keratoderma</Keyword>
        <Keyword MajorTopicYN="N">tyrosine kinase inhibitors</Keyword>
      </KeywordList>
      <CoiStatement>Patent pending for C.G., J.S., S.C., C.B. (Claude Boucheix) and C.B. (Christine Bodemer).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>23</Day>
          <Hour>1</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35453591</ArticleId>
        <ArticleId IdType="pmc">PMC9028469</ArticleId>
        <ArticleId IdType="doi">10.3390/biomedicines10040841</ArticleId>
        <ArticleId IdType="pii">biomedicines10040841</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Zieman A.G., Poll B.G., Ma J., Coulombe P.A., Zieman A.G., Coulombe P.A. Altered keratinocyte differentiation is an early driver of keratin mutation-based palmoplantar keratoderma. Hum. Mol. Genet. 2019;28:2255–2270. doi: 10.1093/hmg/ddz050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddz050</ArticleId>
            <ArticleId IdType="pmc">PMC6602407</ArticleId>
            <ArticleId IdType="pubmed">31220272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zieman A.G., Coulombe P.A. Pathophysiology of pachyonychia congenita-associated palmoplantar keratoderma: New insights into skin epithelial homeostasis and avenues for treatment. Br. J. Dermatol. 2020;182:564–573. doi: 10.1111/bjd.18033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjd.18033</ArticleId>
            <ArticleId IdType="pmc">PMC6814456</ArticleId>
            <ArticleId IdType="pubmed">31021398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samuelov L., Smith F.J.D., Hansen C.D., Sprecher E. Revisiting pachyonychia congenita: A case-cohort study of 815 patients. Br. J. Dermatol. 2020;182:738–746. doi: 10.1111/bjd.18794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjd.18794</ArticleId>
            <ArticleId IdType="pubmed">31823354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu T.T., Eldirany S.A., Bunick C.G., Teng J.M.C. Genotype-structurotype-phenotype correlations in pachyonychia congenita patients. J. Investig. Dermatol. 2021;141:2876–2884.e4. doi: 10.1016/j.jid.2021.03.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jid.2021.03.035</ArticleId>
            <ArticleId IdType="pmc">PMC8922998</ArticleId>
            <ArticleId IdType="pubmed">34116063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith F.J.D., Hansen C.D., Hull P.R., Kaspar R.L., McLean W.H.I., O’Toole E., Sprecher E.  Pachyonychia Congenita. In: Adam M.P., Ardinger H.H., Pagon R.A., Wallace S.E., Bean L.J.H., Mirzaa G., Amemiya A., editors. GeneReviews®[Internet] University of Washington; Seattle, WA, USA: 2017. </Citation>
        </Reference>
        <Reference>
          <Citation>Goldberg I., Fruchter D., Meilick A., Schwartz M.E., Sprecher E. Best treatment practices for pachyonychia congenita. J. Eur. Acad. Dermatol. Venereol. JEADV. 2014;28:279–285. doi: 10.1111/jdv.12098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jdv.12098</ArticleId>
            <ArticleId IdType="pubmed">23363249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hickerson R.P., Leake D., Pho L.N., Leachman S.A., Kaspar R.L. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. J. Dermatol. Sci. 2009;56:82–88. doi: 10.1016/j.jdermsci.2009.07.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jdermsci.2009.07.008</ArticleId>
            <ArticleId IdType="pubmed">19699613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdollahimajd F., Rajabi F., Shahidi-Dadras M., Saket S., Youssefian L., Vahidnezhad H., Uitto J. Pachyonychia congenita: A case report of a successful treatment with rosuvastatin in a patient with a KRT6A mutation. Br. J. Dermatol. 2019;181:584–586. doi: 10.1111/bjd.17276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjd.17276</ArticleId>
            <ArticleId IdType="pubmed">30307612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frommherz L., Has C. Successful treatment of Pachyonychia congenita with Rosuvastatin. J. Eur. Acad. Dermatol. Venereol. JEADV. 2020;34:e480–e482. doi: 10.1111/jdv.16393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jdv.16393</ArticleId>
            <ArticleId IdType="pubmed">32236980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theocharopoulos I., O’Toole E.A. Stopping pachyonychia congenita plantar pain with a statin? Br. J. Dermatol. 2019;181:446–447. doi: 10.1111/bjd.18254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjd.18254</ArticleId>
            <ArticleId IdType="pubmed">31386169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peus D., Hamacher L., Pittelkow M.R. EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. J. Investig. Dermatol. 1997;109:751–756. doi: 10.1111/1523-1747.ep12340759.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1523-1747.ep12340759</ArticleId>
            <ArticleId IdType="pubmed">9406816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schneider M.R., Werner S., Paus R., Wolf E. Beyond wavy hairs: The epidermal growth factor receptor and its ligands in skin biology and pathology. Am. J. Pathol. 2008;173:14–24. doi: 10.2353/ajpath.2008.070942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2353/ajpath.2008.070942</ArticleId>
            <ArticleId IdType="pmc">PMC2438281</ArticleId>
            <ArticleId IdType="pubmed">18556782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greco C., Leclerc-Mercier S., Chaumon S., Doz F., Hadj-Rabia S., Molina T., Boucheix C., Bodemer C. Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 Mutations. JAMA Dermatol. 2020;156:191–195. doi: 10.1001/jamadermatol.2019.4126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamadermatol.2019.4126</ArticleId>
            <ArticleId IdType="pmc">PMC6990711</ArticleId>
            <ArticleId IdType="pubmed">31895432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng X., Jin J., Hu L., Shen D., Dong X.P., Samie M.A., Knoff J., Eisinger B., Liu M.L., Huang S.M., et al.  TRP channel regulates EGFR signaling in hair morphogenesis and skin barrier formation. Cell. 2010;141:331–343. doi: 10.1016/j.cell.2010.03.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2010.03.013</ArticleId>
            <ArticleId IdType="pmc">PMC2858065</ArticleId>
            <ArticleId IdType="pubmed">20403327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang A., Duchatelet S., Lakdawala N., Tower R.L., Diamond C., Marathe K., Hill I., Richard G., Diab Y., Kirkorian A.Y., et al.  Targeted Inhibition of the Epidermal Growth Factor Receptor and Mammalian Target of Rapamycin Signaling Pathways in Olmsted Syndrome. JAMA Dermatol. 2020;156:196–200. doi: 10.1001/jamadermatol.2019.4141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamadermatol.2019.4141</ArticleId>
            <ArticleId IdType="pmc">PMC6990762</ArticleId>
            <ArticleId IdType="pubmed">31895414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noakes R. Olmsted Syndrome: Response to erlotinib therapy and genotype/phenotype correlation. Australas. J. Derm. 2021;62:445–446. doi: 10.1111/ajd.13663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ajd.13663</ArticleId>
            <ArticleId IdType="pubmed">34227679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hidalgo M., Bloedow D. Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of Erlotinib (Tarceva) Semin. Oncol. 2003;30:25–33. doi: 10.1016/S0093-7754(03)70012-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0093-7754(03)70012-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burris H.A., III, Taylor C.W., Jones S.F., Koch K.M., Versola M.J., Arya N., Fleming R.A., Smith D.A., Pandite L., Spector N., et al.  A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2009;15:6702–6708. doi: 10.1158/1078-0432.CCR-09-0369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-09-0369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bouhassira D., Attal N., Fermanian J., Alchaar H., Gautron M., Masquelier E., Rostaing S., Lanteri-Minet M., Collin E., Grisart J., et al.  Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004;108:248–257. doi: 10.1016/j.pain.2003.12.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pain.2003.12.024</ArticleId>
            <ArticleId IdType="pubmed">15030944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basra M.K., Fenech R., Gatt R.M., Salek M.S., Finlay A.Y. The Dermatology Life Quality Index 1994–2007: A comprehensive review of validation data and clinical results. Br. J. Dermatol. 2008;159:997–1035. doi: 10.1111/j.1365-2133.2008.08832.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2133.2008.08832.x</ArticleId>
            <ArticleId IdType="pubmed">18795920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallis T., Poole C.D., Hoggart B. Can skin disease cause neuropathic pain? A study in pachyonychia congenita. Clin. Exp. Dermatol. 2016;41:26–33. doi: 10.1111/ced.12723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ced.12723</ArticleId>
            <ArticleId IdType="pubmed">26358843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brill S., Sprecher E., Smith F.J.D., Geva N., Gruener H., Nahman-Averbuch H., Defrin R. Chronic pain in pachyonychia congenita: Evidence for neuropathic origin. Br. J. Dermatol. 2018;179:154–162. doi: 10.1111/bjd.16217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjd.16217</ArticleId>
            <ArticleId IdType="pubmed">29210461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee G., Lowe P.M. Treatment of Keratin 16 Palmoplantar Keratoderma With Topical Erlotinib. JAMA Dermatol. 2022;158:216–217. doi: 10.1001/jamadermatol.2021.5302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamadermatol.2021.5302</ArticleId>
            <ArticleId IdType="pubmed">34985526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong M.L., Fleming L., Robayo L.E., Widerstrom-Noga E. Utility of the Neuropathic Pain Symptom Inventory in people with spinal cord injury. Spinal Cord. 2020;58:35–42. doi: 10.1038/s41393-019-0338-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41393-019-0338-5</ArticleId>
            <ArticleId IdType="pubmed">31431674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borges J.P., Mekhail K., Fairn G.D., Antonescu C.N., Steinberg B.E. Modulation of Pathological Pain by Epidermal Growth Factor Receptor. Front. Pharmacol. 2021;12:642820. doi: 10.3389/fphar.2021.642820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2021.642820</ArticleId>
            <ArticleId IdType="pmc">PMC8149758</ArticleId>
            <ArticleId IdType="pubmed">34054523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kersten C., Cameron M.G. Cetuximab alleviates neuropathic pain despite tumour progression. BMJ Case Rep. 2012;2012:bcr1220115374. doi: 10.1136/bcr.12.2011.5374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bcr.12.2011.5374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kersten C., Cameron M.G., Mjaland S. Epithelial growth factor receptor (EGFR)-inhibition for relief of neuropathic pain-A case series. Scand. J. Pain. 2013;4:3–7. doi: 10.1016/j.sjpain.2012.11.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.sjpain.2012.11.011</ArticleId>
            <ArticleId IdType="pubmed">29913887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo J., Hu H. Thermally activated TRPV3 channels. Curr. Top. Membr. 2014;74:325–364. doi: 10.1016/b978-0-12-800181-3.00012-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/b978-0-12-800181-3.00012-9</ArticleId>
            <ArticleId IdType="pubmed">25366242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kocot-Kepska M., Zajaczkowska R., Mika J., Wordliczek J., Dobrogowski J., Przeklasa-Muszynska A. Peripheral Mechanisms of Neuropathic Pain-the Role of Neuronal and Non-Neuronal Interactions and Their Implications for Topical Treatment of Neuropathic Pain. Pharmaceuticals. 2021;14:77.  doi: 10.3390/ph14020077.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ph14020077</ArticleId>
            <ArticleId IdType="pmc">PMC7909513</ArticleId>
            <ArticleId IdType="pubmed">33498496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szollosi A.G., Vasas N., Angyal A., Kistamas K., Nanasi P.P., Mihaly J., Beke G., Herczeg-Lisztes E., Szegedi A., Kawada N., et al.  Activation of TRPV3 Regulates Inflammatory Actions of Human Epidermal Keratinocytes. J. Investig. Dermatol. 2018;138:365–374. doi: 10.1016/j.jid.2017.07.852.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jid.2017.07.852</ArticleId>
            <ArticleId IdType="pubmed">28964718</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
